A 2026 animal study found that combining the probiotic VSL#3 with the liver medication obeticholic acid reduced liver fat and improved blood markers of liver health in mice with fatty liver disease. According to Gram Research analysis, the probiotic also altered how the medication moved through the body by changing gut bacteria. However, these results are from mice, not humans, so human studies are needed before this combination could become a treatment option.
Researchers tested whether combining a probiotic mixture called VSL#3 with a liver medication called obeticholic acid could help treat fatty liver disease in mice. According to Gram Research analysis, the combination appeared to reduce liver fat buildup and improve several markers of liver health. The study also found that the probiotic changed how the medication moved through the body by altering gut bacteria. While these early results are encouraging, the findings are from animal studies and need to be tested in humans before doctors can recommend this combination for patients.
Key Statistics
A 2026 animal study published in Nutrients found that mice receiving both VSL#3 probiotic and obeticholic acid showed reduced liver fat buildup and lower cholesterol and bilirubin levels compared to mice receiving either treatment alone.
Research showed that VSL#3 probiotic co-administration increased early plasma concentrations of the active form of obeticholic acid in mice, suggesting the probiotic altered how the medication was processed in the body.
The 2026 study found that VSL#3 probiotic treatment shifted gut bacteria composition toward species with bile salt hydrolase potential, enzymes that modify bile acids and may influence medication metabolism.
The Quick Take
- What they studied: Whether giving mice both a probiotic supplement and a liver medication together would work better than either treatment alone for fatty liver disease
- Who participated: Male laboratory mice that were fed a high-fat diet to develop fatty liver disease similar to what happens in humans
- Key finding: Mice receiving both the probiotic VSL#3 and the medication obeticholic acid showed less liver fat and better blood markers for liver health compared to other groups
- What it means for you: This research suggests a potential new treatment approach for fatty liver disease, but it’s still in early stages. Human studies are needed before this combination could become a standard treatment option
The Research Details
Scientists used laboratory mice to test whether combining a probiotic with a liver medication could improve fatty liver disease. They fed some mice a high-fat diet to create fatty liver disease, similar to what happens in humans. Then they divided the sick mice into groups: some received only the probiotic VSL#3, some received only the medication obeticholic acid, some received both treatments, and some received neither as a control group.
The researchers then examined what happened inside the mice’s bodies. They looked at the bacteria living in the mice’s guts using genetic testing. They measured the different types of bile acids (digestive chemicals) in the mice’s bodies. They checked how much liver fat the mice had and looked at their blood tests. They also tracked how quickly the medication moved through the mice’s bodies and how it was processed.
This type of study in animals helps scientists understand how treatments work before testing them in humans. It allows researchers to look at detailed biological changes that would be difficult to measure in people.
Understanding how probiotics and liver medications interact is important because both are being studied separately for fatty liver disease. This research shows they might work together in unexpected ways by changing gut bacteria and how the body processes the medication. These findings could help guide future human studies and inform how doctors might combine treatments in the future.
This is an early-stage animal study, which means the results are preliminary. The researchers were careful to measure many different biological markers, which strengthens the findings. However, animal studies don’t always translate to humans because our bodies work differently. The study was published in a peer-reviewed journal, meaning other scientists reviewed it before publication. The researchers were transparent about which findings were exploratory and which were primary results, which is a sign of good scientific practice.
What the Results Show
Mice that received both the probiotic VSL#3 and the medication obeticholic acid showed less fat buildup in their livers compared to mice that received only one treatment or neither. The combination group also had better blood test results, including lower cholesterol levels and lower bilirubin (a marker of liver stress).
The probiotic VSL#3 changed the types of bacteria living in the mice’s guts. Specifically, it increased bacteria that have the ability to break down certain bile acids. This change in gut bacteria appeared to affect how the liver medication was processed in the body.
Mice receiving the probiotic showed higher levels of the active form of the liver medication in their blood during the early phase after treatment. This suggests the probiotic changed how the medication was absorbed and processed, which could affect how well it works.
The researchers found that mice receiving the probiotic had lower expression of a specific protein in their intestines called Abcc2. This protein normally helps move certain substances out of intestinal cells. The researchers noted this as an exploratory finding but couldn’t confirm whether this change directly caused the differences in medication levels. The study also showed that the probiotic shifted the balance of bile acids in the mice’s bodies toward more deconjugated forms, which are bile acids that have been chemically modified by bacteria.
Previous research has shown that probiotics can influence gut bacteria and bile acid metabolism, and that obeticholic acid can help reduce liver fat. This study is novel because it’s one of the first to examine what happens when these two treatments are combined. The findings align with the theory that probiotics work partly by changing how the body processes medications and bile acids, supporting earlier research in this area.
This study was conducted in mice, not humans, so the results may not apply directly to people. The sample size and specific number of mice in each group were not clearly reported. Some of the findings were described as exploratory or numerical trends rather than statistically significant results, meaning they might have happened by chance. The researchers could not establish a clear cause-and-effect relationship between the intestinal protein changes and the medication levels. The study was relatively short-term, so we don’t know if these benefits would continue over months or years.
The Bottom Line
Based on this animal research, the combination of VSL#3 probiotic and obeticholic acid appears promising for fatty liver disease, but confidence is low because this is early-stage research. Do not start taking this combination based on this study alone. If you have fatty liver disease, talk to your doctor about proven treatment options like weight loss, exercise, and dietary changes. Future human studies are needed before this combination can be recommended as a standard treatment.
People with fatty liver disease or those at risk for developing it should follow this research, but shouldn’t change their treatment based on these findings alone. Healthcare providers treating fatty liver disease should be aware of this research as it may inform future treatment strategies. Researchers studying probiotics and liver disease will find this work relevant to their field.
This is animal research, so there’s no timeline for human benefits yet. If human studies are started soon, it could take 3 to 5 years or longer to determine if this combination is safe and effective in people. Even if human trials show promise, it would take additional time for regulatory approval before this combination could become a standard treatment option.
Frequently Asked Questions
Can I take VSL#3 probiotic with obeticholic acid for fatty liver disease?
This combination has only been tested in mice so far. While results are encouraging, human studies are needed first. Talk to your doctor before combining any supplements with medications. Current proven treatments for fatty liver disease include weight loss, exercise, and dietary changes.
How do probiotics help with fatty liver disease?
Probiotics may help by changing gut bacteria composition, which affects how your body processes bile acids and medications. A 2026 study found that VSL#3 increased bacteria with bile salt hydrolase enzymes, potentially improving liver health markers in mice.
What is obeticholic acid and how does it treat fatty liver?
Obeticholic acid is a medication that works on bile acid receptors in the body to reduce liver inflammation and fat buildup. It’s being studied as a potential treatment for fatty liver disease, though it’s not yet widely approved for this use.
When will this probiotic and medication combination be available for humans?
This is still in early research stages. Human clinical trials would need to be conducted first, which typically takes several years. Even if trials show promise, regulatory approval would take additional time before this combination could become a standard treatment option.
What should I do now if I have fatty liver disease?
Focus on proven treatments: lose weight if overweight, exercise regularly, eat a healthy diet low in sugar and processed foods, and limit alcohol. Work with your doctor to monitor your liver health through blood tests. Ask your doctor about current treatment options rather than waiting for experimental combinations.
Want to Apply This Research?
- If you have fatty liver disease, track your liver health markers that your doctor monitors: ALT and AST levels (liver enzymes), bilirubin, cholesterol, and triglycerides. Record these values from your blood tests every 3 to 6 months to see if your liver health is improving with your current treatment plan.
- Use the app to log daily habits that improve liver health: minutes of exercise, servings of vegetables, alcohol consumption (if applicable), and water intake. These proven lifestyle changes are currently the best treatment for fatty liver disease and should be the foundation of any treatment plan.
- Set up monthly reminders to log your weight and energy levels. Create a chart to track trends over time. When you have blood work done, photograph your lab results and add them to the app with the date. This helps you and your doctor see whether your current treatment approach is working.
This research is from an animal study and has not been tested in humans. The findings are preliminary and exploratory. Do not start taking VSL#3 or obeticholic acid based on this study alone. If you have fatty liver disease or are concerned about your liver health, consult with a qualified healthcare provider before starting any new supplements or medications. This article is for informational purposes only and should not replace professional medical advice, diagnosis, or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.